New drug aims to wipe out hidden leukemia cells before they return

NCT ID NCT02458014

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia who were in remission but still had tiny amounts of cancer cells detectable (minimal residual disease). The goal was to see if the drug could clear those leftover cells and improve how long patients stay cancer-free. Blinatumomab works by helping the body's immune system find and destroy leukemia cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
blinatumomab (a drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a way to clear hidden leukemia cells and delay or prevent relapse in patients who are in remission but still have traces of the disease.
What could go wrong
This is a small, single-center Phase II trial with only 36 participants, so results may not apply broadly. The drug can cause serious side effects, and it is not a cure—patients may still need a stem cell transplant or other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN COMPLETE REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.